Production and use of IL-6

Details Production and use of IL-6 Production and use of IL-6

1991-06-17

2002-02-19

Mertz, Prema (Department: 1646)

Drug, bio-affecting and body treating compositions

Lymphokine

Interleukin

C514S002600, C514S008100, C514S012200, C530S351000, C435S069520, C435S071100, C435S071200, C435S325000, C435S252300, C435S254110, C435S471000, C435S320100

Reexamination Certificate

active

06348191

ABSTRACT:

BACKGROUND OF THE INVENTION
Hematopoietins or hematopoietic growth factors are proteins that promote the survival, growth and differentiation of hematopoietic cells. The biochemical and biological identification and characterization of certain hematopoietins has been hampered by the small quantities of the factors available from natural sources, e.g., blood and urine. With recombinant genetic engineering techniques, however, some of these hematopoietins have been molecularly cloned, heterologously expressed and purified to homogenei-ty. Among these hematopoietins are colony stimulating factors (CSFs) characterized by the ability to support the growth in vitro of colonies of hematopoietic cells arising from progenitor cells of bone marrow, fetal liver and other organs, e.g. GM-CSF, G-CSF, CSF-1 and IL-3. [See, e.g., D. Metcalf,
Blood,
67(2): 257-267 (1986); Y. C. Yang et al,
Cell,
47(1):3-10 (1986); R. Donahue et al,
Nature,
321:872-875 (1986)].
Subsequent to the filing date of the present inventors' United States priority applications, several publications issued by other researchers describing proteins characterized by other biological activities and names, which were identical to the novel protein, called IL-6 described herein and in the priority applications. See, Haegeman et al,
Eur. J. Biochem.,
159:625-632 (1986) and references cited therein [the 26 kd protein inducible in human fibroblasts]; Zilberstein et al,
EMBO J.,
5:2529-2537 (1986) [IFN-beta-2 with weak interferon activity]; and Hirano et al,
Nature,
324:73-76 (1986) [BCDF or BSF-2 for its B cell stimulatory activity]. See also, published European Patent Application 220,574. Several of these papers reported purification of the natural substance.


REFERENCES:
patent: 4338397 (1982-07-01), Gilbert et al.
patent: 4559302 (1985-12-01), Ingolia
patent: 4675285 (1987-06-01), Clark et al.
patent: 5541088 (1996-07-01), Kishimoto et al.
patent: 0 257 406 (1988-03-01), None
patent: 0 356 180 (1990-02-01), None
patent: 0 363 083 (1990-04-01), None
patent: 0 378 171 (1990-07-01), None
patent: 2063882 (1981-06-01), None
patent: 61115025 (1986-06-01), None
Weissenbach, J. et al., Proc. Natl. Acad. Sci. U.S.A. 77:7152-7156 (1980).
Sehgal, P. et al., Nature 288:95-97 (1980).
Sagar, A. et al., J. Exp. Med. 156:744-755 (1982).
Content, J. et al., Proc. Natl. Acad. Sci. U.S.A. 79:2768-2772 (1982).
Content, J. et al., Eur. J. Biochem. 152:253-257 (1985).
Hirano, T. et al., J. Immunology 133:798-802 (1984).
Hirano, T. et al., Proc. Natl. Acad. Sci. U.S.A. 82:5490-5494 (1985).
Zilberstein, A. et al.,The Interferon System, Serono Symposia, vol. 24: 73-83 (G. B. Rossi & E., Dianzani eds.) New York:Raven Press (1985).
Kikutani, H. et al., J. Immunology 134:990-995 (1985).
Kishimoto, T., Ann. Rev. Immunology 3:133-157 (1985).
Kohase, M. et al., Cell 45:659-666 (1986).
Mule, J. et al., J. Exp. Med. 171:629-636 (1990).
Patchen, M. et al., Blood 77:472-480 (1991).
Kitahara, M. et al., J. Cancer Res. 81:1032-1038 (1990).
Maekawara, T. et al., Int. J. Cancer 45:353-358 (1990).

Affiliated with

Also associated with

Rating

Production and use of IL-6 does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Production and use of IL-6, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Production and use of IL-6 will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2948233